Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: Subgroup analysis of a double-blind, active comparator trial

Cardiovascular Therapeutics

Volumn 28, Issue 6, 2010, Pages 344-349

  Andersen, Karl ^a   Weinberger, Myron H ^b   Egan, Brent ^c   Constance, Christian M ^d   Wright, Melanie ^e   Lukashevich, Valentina ^e   Keefe, Deborah L ^e  

^a UNIVERSITY OF ICELAND   (Iceland)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ACE inhibitor; Aliskiren; Direct renin inhibitor; Ramipril; Stage 2 hypertension

Indexed keywords

ALISKIREN; RAMIPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TREATMENT DURATION;

ADULT; AGED; AMIDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RAMIPRIL; RENIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 78449251704     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00148.x     Document Type: Article

References (13)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R,. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903 - 1913.
2. Mancia G, De Backer G, Dominiczak A, et al,. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105 - 1187. (Pubitemid 46924065)
3. Volpe M, Tocci G, Trimarco B, et al,. Blood pressure control in Italy: Results of recent surveys on hypertension. J Hypertens 2007; 25: 1491 - 1498.
4. Chobanian AV, Bakris GL, Black HR, et al,. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206 - 1252.
5. Azizi M, Webb R, Nussberger J, Hollenberg NK,. Renin inhibition with aliskiren: Where are we now, and where are we going? J Hypertens 2006; 24: 243 - 256.
6. Nussberger J, Wuerzner G, Jensen C, Brunner HR,. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril. Hypertension 2002; 39: E1 - E8.
7. Frampton JE, Curran MP,. Aliskiren: A review of its use in the management of hypertension. Drugs 2007; 67: 1767 - 1792.
8. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL,. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589 - 599.
9. Pickering TG, Hall JE, Appel LJ, et al,. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45: 142 - 161.
10. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D,. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245 - 1249.
11. Sander GE,. Hypertension in the elderly. Curr Hypertens Rep 2004; 6: 469 - 476.
12. Alderman MH, Cohen H, Madhavan S,. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130 - 1134.
13. Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A,. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2008; 22: 266 - 274.